Key result
Quercetin reduces microinfarction size by ~8 percentage points after coronary microembolization by inhibiting ferroptosis.
Why the study?
Ferroptosis has been implicated in CME-induced myocardial injury, but the precise mechanism by which quercetin regulates ferroptosis during CME-mediated myocardial injury remains unclear.
Does quercetin attenuate ferroptosis-associated myocardial injury in a rat model of coronary microembolization?
Does quercetin attenuate ferroptosis-associated myocardial injury in a rat model of coronary microembolization?
Absolute Event Rate: 10.28% vs 17.95%
p-value: p=<0.05
Quercetin demonstrates cardioprotective effects in a rat model of coronary microembolization by reducing infarct size and inhibiting ferroptosis through the Nrf2/HO-1 pathway.
Quercetin attenuates microinfarction in rat CME via ferroptosis inhibition; leaves open human translation pending clinical trials.
Objectives: Coronary microembolization (CME) significantly contributes to the progression of heart failure and is strongly associated with adverse clinical outcomes in patients. Ferroptosis has been implicated in CME-induced myocardial injury. Quercetin has well-documented anti-inflammatory and antioxidant properties and shows therapeutic potential in coronary artery disease. However, its precise mechanism for regulating ferroptosis during CME-mediated myocardial injury remains unclear. This study aims to elucidate the therapeutic effects of quercetin and its underlying molecular mechanisms that regulate ferroptosis in cardiomyocytes following CME. Materials and Methods: The Sprague-Dawley(SD) rats were randomly divided into four groups (n=7 each): Sham, CME, CME+Quercetin (Que), and CME+Quercetin+ML385 (Que+ML385). The CME model was produced by injecting microspheres into the left ventricles. We administered pharmacological treatments as follows: The Que and Que+ML385 groups received daily oral quercetin (250 mg/kg) starting 7 days before model induction until the procedure day. Additionally, we pretreated the Que+ML385 group with intraperitoneal injection of ML385 (30 mg/kg) 2 hr before CME induction. The comprehensive evaluations include cardiac function assessment, quantification of serum biomarkers of myocardial injury, cardiac tissue histology, and analysis of ferroptosis-related molecular markers to evaluate quercetin's therapeutic effects. Results: Quercetin pretreatment significantly improved cardiac function, reduced serum markers of myocardial injury, and decreased microinfarction size. At the molecular level, quercetin up-regulated Nrf2 and HO-1 expression and attenuated biochemical markers of cardiomyocyte ferroptosis. However, ML385 co-treatment attenuated this protective effect. Conclusion: Quercetin may inhibit ferroptosis in cardiomyocytes by activating the Nrf2/HO-1 signaling pathway, thereby improving CME-related cardiac dysfunction and reducing myocardial injury.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied Coronary microembolization-induced myocardial injury (n=28). Quercetin vs. Coronary microembolization (CME) alone was evaluated on Myocardial microinfarction area (%) (p=<0.05). Quercetin pretreatment significantly reduced microinfarction size (10.28% vs 17.95%) and improved cardiac function after coronary microembolization by inhibiting cardiomyocyte ferroptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: